Alector Inc

Alector maintains a strong liquidity position with $65.8 million in cash and equivalents, which is 25.8% of total assets, and a current ratio of 3.83, indicating the company can cover its short-term liabilities multiple times over. The company's price-to-book ratio of 8.95 suggests a premium valuation relative to its book value, while the debt-to-equity ratio of 0.32 indicates a conservative capital structure with limited leverage. Despite a revenue of $21.05 million, Alector reported a net loss of $142.93 million and an operating loss of $156.01 million, reflecting the high R&D costs typical in the biotechnology industry. The return on equity of -4.66% and return on assets of -0.49% underscore the company's unprofitability, which is not uncommon for early-stage biotech firms with no commercial products yet. Alector's revenue is not segmented by product or geography in the latest financial data, but the company's focus is on neurodegenerative diseases, with clinical-stage programs in Alzheimer's and Parkinson's. The company's geographic exposure is likely concentrated in the United States, as is typical for biotech firms, though no specific geographic breakdown is provided in the available data. The company's outlook for the current fiscal year is for continued losses, with no indication of near-term revenue growth. The operating cash flow of -$184.03 million and free cash flow of -$137.25 million highlight the ongoing cash burn, which is expected to continue as the company advances its pipeline. Analysts have a mixed outlook, with a mean price target of $3.10 and a median of $2.00, suggesting limited upside potential in the near term. Alector's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital expenditures are minimal at -$41,000, and there are no significant dilution sources identified in the latest filings. The company's valuation is supported by its pipeline of clinical-stage assets, but the high cash burn and lack of commercial products remain key risks. Recent events include the continued advancement of its lead programs, including AL001 and AL002, in clinical trials. The company has also engaged in strategic collaborations to support its research and development efforts. No major regulatory or legal events have been reported in the latest filings, and the company's risk assessment remains stable.